How effective is Synercid for different infections?
How effective is Synercid for different infections?
Seven phase III development studies of quinupristin/dalfopristin (Synercid) sponsored by the drug's manufacturer, Rhone-Poulenc Rorer in Collegeville, PA, examined the efficacy of the new drug for these three indications:
· nosocomial pneumonia;
· community-acquired pneumonia (CAP);
· complicated skin and skin-structure infection (C-SSSI).
In addition, an emergency-use program (EUP) was conducted, mostly for patients with vancomycin-resistant Enterococcus faecium (VREF) infection.
A regimen of 7.5 mg/kg of quinupristin/ dalfopristin every 12 hours was administered to CAP and C-SSSI patients. Patients with nosocomial pneumonia and in the EUP received 7.5 mg/kg of the drug every eight hours.
Quinupristin/dalfopristin was compared to vancomycin in patients with nosocomial pneumonia; it was compared to ceftriaxone plus erythromycin in CAP patients; and it was compared to vancomycin or oxacillin/cefazoline for C-SSSI patients.
The efficacy of quinupristin/dalfopristin in patients with a positive blood culture at study entry in each indication is shown in the accompanying table (see chart, p. 57) as the "Bacteriologic Response Rate." Please note that there is a "N/A" comparator bacteriologic response for EUP and VREF patients because they had resistant infections, and there were no other antimicrobial agents available to treat them.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.